《生命科学》 2021, 33(7): 869-875

微小RNA与高血压关系研究进展

陶臻博 , 张泽波 , 何　昕 , 张莉娜^*

宁波大学医学院浙江省病理生理学技术研究重点实验室，宁波 315211

摘　要：

原发性高血压(essential hypertension, EH) 是一个重要的公共卫生问题，是多种心血管疾病的危险因素。微小RNA (microRNA, miRNA) 是一种非编码的小RNA，在转录后水平调控靶mRNA 的表达。近年来大量研究表明，miRNA 通过多种途径参与到高血压的发生发展中，包括引发血管内皮细胞功能障碍、血管平滑肌细胞的表型转化以及对肾素- 血管紧张素系统的过激反应等。该文综述了近年来miRNA 在高血压中的研究进展，以期阐明其在高血压发生发展中的作用机制，为探索高血压新的治疗靶点提供思路。

通讯作者：张莉娜 , Email:zhanglina@nbu.edu.cn

Research progress on the relationship between miRNA and hypertension

TAO Zhen-Bo , ZHANG Ze-Bo , HE Xin , ZHANG Li-Na^*

Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo University, Ningbo 315211, China

Abstract:

Essential hypertension is an important public health problem, and is a risk factor for many kinds of cardiovascular diseases. MicroRNAs (miRNAs) are small non-coding RNAs that regulate the expression of target mRNAs at the post-transcriptional level. In recent years, a large number of studies have shown that miRNAs are involved in the occurrence and development of hypertension through a variety of ways, including triggering vascular endothelial cell dysfunction, phenotype transformation of vascular smooth muscle cell, and overreaction to renin-angiotensin system, etc. In this article, the research progress of miRNA in hypertension in recent years is reviewed, with a view to elucidate its mechanism in the occurrence and development of hypertension and to provide ideas for exploring new therapeutic targets for hypertension.

Communication Author：ZHANG Li-Na , Email:zhanglina@nbu.edu.cn